SUPREP® Bowel Prep Kit is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. SUPREP Bowel Prep Kit was approved by the FDA for bowel cleansing in August 2010.
SUPREP Bowel Prep Kit does not contain sodium phosphate, a type of salt found in some bowel preparations. FDA notified healthcare professionals and consumers of reports of acute phosphate nephropathy, a type of acute renal failure, that is a rare, but serious adverse event associated with the use of oral sodium phosphates (OSP) for bowel cleansing.
SUPREP Bowel Prep Kit is taken as a split-dose regimen: A split-dose regimen means that you take two 6-ounce bottles of SUPREP. You will need to take one 6-ounce bottle the evening before your colonoscopy and a second 6-ounce bottle the morning of your colonoscopy. It is important to drink the additional water as recommended in the Instructions for Use.
Ask your doctor if the SUPREP Bowel Prep Kit is right for you.
For more information about the SUPREP Bowel Prep Kit, click here.
Click here for full Prescribing Information and Medication Guide
Braintree Laboratories Code of Conduct
Braintree Laboratories California Health and Safety Code Statement
SUPREP® Bowel Prep Kit is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. Most common adverse reactions (>2%) are overall discomfort, abdominal distention, abdominal pain, nausea, vomiting and headache. Use is contraindicated in the following conditions: gastrointestinal (GI) obstruction, bowel perforation, toxic colitis and toxic megacolon, gastric retention, ileus, known allergies to components of the kit. Use caution when prescribing for patients with a history of seizures, arrhythmias, impaired gag reflex, regurgitation or aspiration, severe active ulcerative colitis, impaired renal function or patients taking medications that may affect renal function or electrolytes. Use can cause temporary elevations in uric acid. Uric acid fluctuations in patients with gout may precipitate an acute flare. Administration of osmotic laxative products may produce mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Patients with impaired water handling who experience severe vomiting should be closely monitored including measurement of electrolytes. Advise all patients to hydrate adequately before, during, and after use. Each bottle must be diluted with water to a final volume of 16 ounces and ingestion of additional water as recommended is important to patient tolerance.